[1] Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study[J]. Am J Cancer, 1932, 16: 1358-1414.
[2] 李麦冬, 胡长路. 多原发癌176例临床分析[J]. 安徽医药, 2017, 21(12): 2222-2224.
[3] Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[4] 田建辉, 罗斌, 刘嘉湘. 从1例异时多原发癌探讨机体内环境紊乱在恶性肿瘤发病中的作用[J]. 现代肿瘤医学, 2015, 23(23): 3520-3521.
[5] 叶天仪, 姚洪文, 吴令英, 等. 34例子宫内膜癌合并结直肠癌双原发癌的临床特征及其与Lynch综合征关系分析[J]. 中国肿瘤临床, 2015, 42(8): 432-436.
[6] Xia L L, Liu Y Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]. Oncologist, 2019, 24(Suppl-1): S31-S41.
[7] 张娣, 黄架旗, 张初峰, 等. PD-1/PD-L1免疫检查点抑制剂在肺癌中的研究进展[J]. 中国肺癌杂志, 2019, 22(6): 369-379.
[8] 雷奇, 周爱萍, 杜春霞. 胃癌合并多原发癌的临床特征与治疗的研究进展[J].中国肿瘤生物治疗杂志, 2021, 28(4): 410-415.
[9] Tabor M P, Brakenhoff R H, Ruijter-Schippers H J, et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion[J]. Am J Pathol, 2002, 161(3): 1051-1060.
[10] Zhang W L, Zhu Z L, Huang M C, et al. Susceptibility of multiple primary cancers in patients with head and neck cancer: nature or nurture?[J]. Front Oncol, 2019, 9: 1275.
[11] Tanjak P, Suktitipat B, Vorasan N, et al. Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study[J]. BMC Cancer, 2021, 21(1): 1045.
[12] Song C K, Yu D H, Wang Y J, et al. Dual primary cancer patients with lung cancer as a second primary malignancy: a population-based study[J]. Front Oncol, 2020, 10: 515606.
[13] 蔡玉烂. 234例多原发癌患者的临床特征及预后分析[D]. 杭州: 浙江大学, 2018.
[14] 李桃, 赵敏, 周颖, 等. 结肠癌肺转移伴原发性肺癌1例[J]. 临床与实验病理学杂志, 2019, 35(12): 1494-1495.
[15] 黄欣, 钱垠, 朱翔. “肺与大肠相表里”与同时性双原发癌[J]. 中国中医基础医学杂志, 2013, 19(10): 1223-1224, 1230.
[16] 王俊, 荆翌峰, 韩邦旻. 外周淋巴细胞亚群分布与前列腺癌并多原发癌关系的病例对照研究[J]. 临床泌尿外科杂志, 2020, 35(6): 423-425, 430.
[17] 王智, 刘涛. 含肺癌多原发癌七例临床分析[J]. 临床医学, 2018, 38(3): 30-33.
[18] Xian Q Y, Li X D, Zhang H Y, et al. Ternary cancer comprising prostatic cancer, esophageal cancer, and gastric cardia cancer: a case report and literature review[J]. Int J Clin Exp Pathol, 2020, 13(12): 3181-3186.
[19] Jayarajah U, Basnayake O, Wijerathne P, et al. A rare occurrence of three primary malignancies of the rectum, breast, and kidney in the same patient: a case report and review of the literature[J]. Case Rep Surg, 2019, 2019: 1716029.
[20] 孙海燕, 潘战宇, 张新伟, 等. 40例多原发癌姑息治疗多学科会诊临床分析[J]. 中国肿瘤临床, 2016, 43(15): 674-678.
[21] Li G Q, Yao J, Wu T N, et al. Triple metachronous primary cancer of uterus, colon, and breast cancer: a case report and review of the literature[J]. Medicine, 2020, 99(34): e21764.
[22] 孙俊杰, 李双庆. 多原发癌病因及发病机制的探索[J]. 中国全科医学, 2017, 20(9): 1136-1141.
[23] 李中晨, 任正刚. 肿瘤免疫检查点抑制剂联合治疗策略及临床应用[J]. 中国临床医学, 2020, 27(6): 909-916.
[24] Yasuda T, Hiraga J, Narita M, et al. Nivolumab effective for gastric and lung cancers but not for multiple myeloma in a multiple primary cancer patient[J]. Case Rep Hematol, 2021, 2021: 9965371.
[25] 斯晓燕, 何春霞, 张丽, 等. 免疫检查点抑制剂相关皮肤不良反应诊治建议[J]. 中国肺癌杂志, 2019, 22(10): 639-644.
[26] Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer[J]. JAMA Oncol, 2019, 5(7): 1043-1047.
[27] 罗靖茹. 胃癌多重癌临床分析及PD-L1表达的临床意义[D]. 南昌: 南昌大学, 2016. |
